Registry for fecal microbiota transplants in Clostridium difficile infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national cohort registry in France for patients undergoing fecal microbiota transplantation (FMT) for Clostridium difficile infections (CDI). It will collect data on the methods used, efficacy, and side effects of FMT, as well as information on stool donors. The study addresses the increasing incidence and severity of CDI, particularly in recurrent cases, which pose significant therapeutic challenges. By evaluating the safety and effectiveness of FMT, the study seeks to provide valuable insights into this treatment option.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients :

* Adult patient with an indication for FMT for CDI (severe refractory CDI, recurrent CDI);
* Informed written consent

Donors:

* Adult (18 years or older)
* Informed Written consent

Exclusion Criteria:

* insufficient level of understanding of written and spoken French language

Where it's running

• Gastroenterology Department of Saint Antoine Hospital
  Paris, France Recruiting

Study contacts

• Study coordinator: Harry SOKOL, MD, PhD
• Email: harry.sokol@aphp.fr
• Phone: 0033 1 49 28 31 62

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VE303 for preventing recurrent Clostridioides difficile infections

  This study is testing a new treatment called VE303 to see if it can help prevent Clostridioides difficile infections from coming back in people who are at high risk.

  Recruiting at 130 sites Phase 3 Vedanta Biosciences, Inc. · Huntsville, Alabama and 214 other locations · NCT06237452

• Analyzing the evolution and bacterial clearance of Clostridioides difficile infections

  This study looks at how Clostridioides difficile infections change over time and how well different treatments work for French-speaking adults in the hospital.

  Recruiting Fondation Hôpital Saint-Joseph · Paris · NCT06030245

• Orally ingested yeast designed to express a tetra-specific anti-toxin for Clostridioides difficile safety study

  This first-in-human trial tests a yeast-based medicine (FZ002) to see if it is safe and tolerable for adults with no active infection, using a placebo for comparison.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Knoxville, Tennessee · NCT07649096

• Oral vancomycin to prevent C. difficile infection in critically ill adults

  This trial sees if taking oral vancomycin can prevent C. difficile infection in critically ill adults who are receiving systemic antibiotics.

  Recruiting Phase 2/3 Riverside University Health System Medical Center · Moreno Valley, California · NCT07221370

• Investigating Clostridium Difficile Infection in Infants

  This study looks at how common Clostridium difficile infections are in infants and what factors might increase the risk, to help improve diagnosis and treatment for these young patients.

  Recruiting First People's Hospital of Hangzhou · Hangzhou, Zhejiang, China · NCT06703918

• Investigating factors related to Clostridioides difficile infection recurrence

  This study is trying to find out how certain body factors, like gut bacteria and genetics, affect the chances of Clostridioides difficile infection coming back in adults who have already been diagnosed with it.

  Recruiting at 12 sites Hospital Universitario de Valme · Alicante, Alicante and 14 other locations · NCT04801862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.